Mom and Baby Beat 1-in-a-Million Odds to Survive the ‘Rarest of Pregnancies’

This photo provided by the family shows, from left, Kaila, Suze, Ryu and Andrew Lopez at Cedars-Sinai hospital in Los Angeles in August 2025 – family photo

A Los Angeles woman recently celebrated the first Christmas with her baby boy, Ryu, born to truly remarkable circumstances.

Ryu developed outside his mother’s womb, and remained hidden for months behind an ovarian cyst that grew to be the size of a basketball. It was so unbelievable, the surgical/OBGYN team that delivered Ryu documented it for a case study in a medical journal.

The manner in which Ryu came into being represents a circumstance that’s “far, far less than 1 in a million,” said Dr. John Ozimek, medical director of labor and delivery at Cedars-Sinai in Los Angeles, where Ryu was born. “I mean, this is really insane.”

Now 41, Suze Lopez has always had an irregular cycle, so missed periods—even consecutive ones—are a normal occurrence. It was almost 20 years ago that she was diagnoses with a pair of ovarian cysts, one of which was removed immediately, and one of which was not.

So in early 2025 when Lopez noted her abdomen swelling, her first thought was the cyst. She never felt kicking, and never had morning sickness—and indeed her instinct was at least partly correct.

The pressure and pain in her abdomen grew as days passed, and she was certain that, even if it risked her ability to conceive again, it was time to remove the other cyst which unbeknownst to her had grown to weigh a mind-boggling 22 pounds.

She needed a CT scan to prepare for surgery, which required a pregnancy test for the radiation, and to her utter surprise the test came back positive. Lopez was delighted, but the pain and discomfort grew and soon she had to be hospitalized at Cedars-Sinai where her medical team found a near fully-developed fetus in an amniotic sack lodged against her pelvis.

The term for where the fetus develops is “implants” and the term for a fetus that implants outside of the womb is an “ectopic pregnancy.” Almost all of these go on to rupture and hemorrhage. As such, fetal mortality can be as high as 90% in such cases and birth defects are seen in about 1 in 5 surviving babies, SF Gate reports.

However, because fetal Ryu implanted against the pelvic wall and not against the liver, it was far more manageable, and the reason why Lopez didn’t have more pain earlier.

Lopez and her boy beat the odds, despite a mammoth surgical procedure that both delivered Ryu at 8 pounds and removed the ovarian cyst—together weighing as much as an adult bobcat. During the procedure, Lopez lost half her blood, and had to be continually given transfusions.

“The whole time, I might have seemed calm on the outside, but I was doing nothing but praying on the inside,” Andrew Lopez, Suze’s husband, told SF Gate. “It was just something that scared me half to death, knowing that at any point I could lose my wife or my child.”Instead, they both survived without any maleffects. Ryu “completes” their family, said his mother, and recently celebrated his first Christmas alongside his older sister Kaila. Mom and Baby Beat 1-in-a-Million Odds to Survive the ‘Rarest of Pregnancies

Read More........→July 28, 2026

Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection

A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants.

Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa.

The results were nothing short of extraordinary—100% efficacy, not a single young woman contracted HIV.

This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men—and to those of all ages. 5,000 participants took part.

The result was the same: 99.9% reduction in infection rates.

Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention—a pill called Truvada or Descovy taken daily.

These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who’s tried to stick to a once-a-day pill regime long-term will agree, it’s not an easy thing to maintain month after month.

By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda.

Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments.

Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo.

It works to break down the HIVs capsid shell by binding to an “highly conserved” protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains—presenting the perfect target for the drug.

In layman’s terms, the drug then works through the protein to disrupt the capsid shell, which the virus ‘takes down’ and ‘builds up’ several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle.

Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs.Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027 Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection

Read More........→July 13, 2026